Healthcare conglomerate is facing increasing competition for some of its older drugs
Revenue grows 1% in second quarter to $9.84 billion, beating estimates
Company fails to persuade advisory panel to back exponential expansion of market for cardiovascular drug
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices